Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study to Evaluate the Performance and Potential Benefits of an Assistive Artificial Intelligence Device ScanNav Anatomy Peripheral Nerve Block - US V1.0 for Ultrasound-guided Regional Anesthesia

31 marzo 2022 aggiornato da: IntelligentUltrasound Limited

This is a single-center, prospective study to be undertaken at University of Oregon, Portland, USA. The aim is to provide data on the clinical performance of ScanNav Anatomy PNB for identification of anatomical structures during UGRA scanning, in particular:

  1. Assess the benefits of the device to intended users when supervising a trainee who is performing UGRA scanning.
  2. Assess the benefits of the device when intended users perform UGRA scanning.
  3. Assess risk mitigation by the intended users when performing UGRA scanning.

Panoramica dello studio

Descrizione dettagliata

Background:

The American Society of Regional Anesthesia and Pain Medicine (ASRA) has published evidence-based assessment of ultrasound-guided regional anesthesia (Neal et al., 2010) concluding that ultrasound guidance is superior or equal to other non-ultrasound nerve localization techniques. A subsequent publication from ASRA (Neal et al., 2016), has strengthened their position of ultrasound guidance being superior than other methods, including for the reduction of local anesthetic systemic toxicity. However, ultrasound-guided regional anesthesia (UGRA) is a difficult technique to master. A key activity of UGRA is ultrasound image interpretation (Sites et al., 2009) which ScanNav Anatomy PNB is designed to support.

Methodology:

15 participants (anesthesiologists capable of independently performing UGRA) will be recruited to evaluate the performance and benefit of ScanNav Anatomy PNB device in person, by scanning 2 healthy models (n=1 BMI<30, n=1 BMI>=30 kg/m2).

The device performance and benefits will be ascertained once the scanning session for each block is complete by use of a structured questionnaire.

  • Participants will be asked to scan a model with and without the use of ScanNav Anatomy PNB. The order of with/without the device will be randomized between participants.
  • Participants will also be asked to supervise a trainee (another healthcare professional qualified to perform the UGRA procedure under supervision) while they are scanning models with and without ScanNav Anatomy PNB aid. The participant will always use the device first before supervising the trainee.
  • The above will be performed on 2 models from different BMI categories (n=1 BMI<30, n=1 BMI>=30 kg/m2; total scans n=16).
  • The order of models will be randomized between participants.
  • All 9 supported regions will be evaluated; each region will be scanned/evaluated at least 3 times.

Data collection

- Participants and trainees will be asked to complete a structured questionnaire to assess the device performance and clinical benefits at the end of scanning for the block.

Data analysis:

  • Data will be aggregated and evaluated on safety critical structure type basis.
  • Quantitative data obtained from the participants will be presented as frequencies and expressed as percent of total or as mean ± s.d. where appropriate.

The collected data and overall performance and benefits of ScanNav Anatomy PNB will be evaluated and summarized by presence and absence of ScanNav Anatomy PNB assistance, trainee and stratified by low/high BMI model.

Independent expert evaluation

  • The scans be recorded during the study sessions. These scans will be post processed to short clips (10 seconds prior to obtaining optimum view) and sent for evaluation to an independent expert panel.
  • The expert panel will be asked to evaluate the scans and the ScanNav Anatomy PNB highlighting performance independently from the participant. The majority opinion (at least 2/3) will be obtained to establish the agreement (e.g., yes/yes/no = yes)
  • The answers obtained during the scan session from participants will be compared to expert panel view. Independent comparisons between performance assessment will be made, providing that the expert panel view is the 'ground truth'.
  • Data will be evaluated and presented by safety structure on each model and overall (i.e., total for each class of safety critical structure; nerve, artery etc.).

Tipo di studio

Osservativo

Iscrizione (Effettivo)

34

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health & Science University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Participants All participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.

Trainees All trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner.

Models 4 models will be selected carefully based on their BMI inclusion criteria.

Descrizione

Participant Inclusion criteria

  1. Completed advanced training (e.g., fellowship) in or hold a qualification related to UGRA
  2. Regularly delivers direct clinical care using UGRA, including for 'awake' surgery where indicated
  3. Member of a relevant professional society (e.g., ASA, ASRA, ESRA, RA-UK)
  4. Regularly teach UGRA in the course of their clinical work, including advanced techniques where indicated

Participant exclusion criteria

  1. Unwilling or unable to provide informed consent.
  2. Involved in development of the ScanNav Anatomy PNB device.

Trainee Inclusion criteria

  1. U.S. board-eligible/board-certified health practitioner who holds a qualification licensing to perform UGRA
  2. NOT capable or confident of independent UGRA practice

Trainee exclusion criteria

  1. Unwilling or unable to provide informed consent.
  2. Involved in development of the ScanNav Anatomy PNB device.

Models Inclusion Criteria

  1. Male or female, at least 18 years of age;
  2. Able to comprehend and sign the Informed Consent prior to enrolment in the study.
  3. To fit either BMI category: BMI <30 OR BMI >=30

Model Exclusion Criteria

  1. Aged <18 years of age or over 60 years or age
  2. Unwilling or unable to provide informed consent.
  3. BMI> 39 kg/m2
  4. Known pathology of the area to be scanned.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: Coorte
  • Prospettive temporali: Prospettiva

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Participant
All 15 participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.
All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
Trainee
All 15 trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner
All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Obtaining the correct ultrasound view
Lasso di tempo: 6 months
Number of participants obtaining the correct ultrasound view [majority view, at least 8/15 participants in agreement]
6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Identifying anatomical structures
Lasso di tempo: 6 months
Number of participants identifying the correct anatomical structures in adult patients up to BMI 35 kg/m2 [majority view, at least 8/15 participants in agreement]
6 months
Effect of supervision in anatomical structure identification
Lasso di tempo: 6 months
Number of participants identifying the correct anatomical structures while being supervised in UGRA scanning [majority view, at least 8/15 participants in agreement]
6 months
Measuring operator confidence
Lasso di tempo: 6 months
Number of participants with improved confidence [majority view, at least 8/15 participants in agreement]
6 months
Number of errors in anatomy recognition by participants
Lasso di tempo: 6 months
Number of errors in anatomy recognition by participants [per class of safety critical structure, for all models]
6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Glenn Woodworth, MD, Oregon Health and Science University
  • Investigatore principale: James Bowness, MD, University of Oxford & Royal Gwent Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 maggio 2021

Completamento primario (Effettivo)

22 maggio 2021

Completamento dello studio (Effettivo)

30 novembre 2021

Date di iscrizione allo studio

Primo inviato

25 maggio 2021

Primo inviato che soddisfa i criteri di controllo qualità

1 giugno 2021

Primo Inserito (Effettivo)

9 giugno 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 aprile 2022

Ultimo aggiornamento inviato che soddisfa i criteri QC

31 marzo 2022

Ultimo verificato

1 giugno 2021

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IU2021_AG_08

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

No

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Ultrasound scanning

3
Sottoscrivi